Texas Tylenol Lawsuit: Did Drug Giants Hide Autism Risks From Expecting Mothers?

The lawsuit filed by Texas Attorney General Ken Paxton against Johnson & Johnson and Kenvue has evolved into a pivotal legal and political battle that combines corporate ethics with public health issues. The case focuses on allegations that Tylenol’s manufacturers misrepresented the medication’s safety for expectant mothers while neglecting potential risks associated with autism and ADHD in kids. The lawsuit, which was filed in late October 2025, has quickly become a national conversation topic regarding consumer protection and medical transparency.

Paxton’s argument is based on the idea that despite being aware of research indicating possible neurodevelopmental risks, Johnson & Johnson and its subsidiary, Kenvue, continued to market Tylenol as safe for expectant mothers. His office claims that the companies’ deceptive advertising “misled millions while endangering the unborn,” arguing that these actions violate Texas’ consumer protection laws. Paxton claimed in his public remarks that “Big Pharma betrayed America by profiting off pain and hiding the truth,” a claim that has sparked a national uproar in politics and society.

Kenvue responded quickly and firmly. “I stand with the global medical community, which affirms the safety of acetaminophen when used correctly,” the company said. It underlined that the claims made in the lawsuit are not supported by the scientific consensus. Johnson & Johnson has also maintained that there is insufficient evidence to support the lawsuit, claiming that the purported connections between acetaminophen and autism have not been validated. Their defense has a very assertive tone that aims to convey both assurance and accountability.

Table – Texas Tylenol Lawsuit Overview

Category	Details
Case Title	State of Texas v. Johnson & Johnson and Kenvue Inc.
Plaintiff	Texas Attorney General Ken Paxton
Defendants	Johnson & Johnson, Kenvue Inc.
Filed	October 28, 2025
Court	Texas State Court
Key Allegation	Deceptive marketing of Tylenol as safe for pregnant women despite alleged autism risks
Core Legal Basis	Texas Deceptive Trade Practices Act; Texas Uniform Fraudulent Transfer Act
Requested Damages	Tens of billions of dollars
Lead Counsel	Ashley Keller, Keller Postman Law Firm
Political Context	Paxton running for U.S. Senate; lawsuit aligns with anti-Big Pharma platform
Reference	www.texasattorneygeneral.gov

This lawsuit comes at a contentious political time. Paxton, who is already well-known for his combative stance on corporate responsibility, has utilized the case to support his populist platform as a candidate for the U.S. Senate. His claim that “by holding Big Pharma accountable, we will help Make America Healthy Again” is part of a larger campaign strategy that links moral and economic renewal with health policy. Despite being divisive, the rhetoric has been incredibly successful in gaining support from voters who are dubious about the influence of pharmaceuticals.

The underlying scientific controversy is still complicated. Prenatal acetaminophen use has been statistically linked to developmental disorders in some studies, such as those from Harvard and Mount Sinai, but other studies, such as the large Swedish sibling study of more than two million births, found no direct causal link. The results were “exceptionally clear in showing no consistent pattern,” according to Dr. Brian Lee, an epidemiologist from Drexel University who co-authored the study. However, he admitted that the ambiguity itself feeds public anxiety by creating a disconnect between social perception and scientific consensus.

Ashley Keller, a Chicago lawyer, is spearheading the lawsuit, which takes a different approach from conventional personal injury claims. It focuses on purportedly fraudulent transfers of liability and misleading trade practices rather than demonstrating medical harm. Paxton’s office calls the move “a calculated effort to evade responsibility” and accuses Johnson & Johnson of spinning off Kenvue in order to isolate legal risk. If effective, this strategy might significantly increase the legal exposure of pharmaceutical firms involved in public health disputes.

The corporate litigation history of Texas lends credence to this endeavor. Johnson & Johnson has already paid out significant settlements to the state, including $700 million for deceptive talc-based product claims and $290 million for its involvement in the opioid crisis. These triumphs established Paxton as a tenacious opponent of corporate wrongdoing, placing his Tylenol case in the context of his larger goal to “restore honesty in health care.” Many Texans who see pharmaceutical companies as powerful and unaccountable have responded favorably to his straightforward, populist, and strongly moralistic legal stance.

It’s especially high stakes for Johnson & Johnson. Tylenol is more than just a product; it is a cultural representation of comfort and dependability. Over the years, the brand’s reputation for reliability has grown, and its red and white packaging is a staple in medicine cabinets all over the nation. That trust is undermined by claims that it is even remotely linked to pregnancy-related harm. Corporate analysts caution that, especially in a time when consumer confidence is eroding, reputational harm may be much more difficult to recover than monetary losses.

Wider conflicts in American healthcare are also reflected in the lawsuit. It calls into question how businesses should convey risk when science is still inconclusive. The state’s lead attorney, Keller, put it this way: “Transparency isn’t optional—it’s an ethical duty—when uncertainty exists.” According to his perspective—which is held by many consumer advocates—withholding information compromises public autonomy and medical trust, even in the face of scientific ambiguity. This viewpoint has had a significant impact on lawmakers who support stricter disclosure requirements for pharmaceutical advertising.

This case’s convergence of politics, law, and science has been likened to significant corporate reckoning events, such as the opioid settlements in the 2020s and Big Tobacco in the 1990s. All of those cases started out with skepticism and ended up changing public policy. It’s unclear if the Texas Tylenol lawsuit will take a similar course, but its cultural significance is already clear. It has rekindled discussions about informed consent, the boundaries of regulatory supervision, and businesses’ obligations to strike a balance between caution and profit.